Brooks Laboratories Ltd (BROOKS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 539063,
    "name": "Brooks Lab.",
    "stock_name": "Brooks Lab.",
    "full_name": "Brooks Laboratories Ltd",
    "name_url": "stocks-analysis/brooks-lab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "60.00",
    "chg": -0.19,
    "chgp": "-0.32%",
    "dir": -1,
    "prev_price": "60.19",
    "mcapval": "176.74 Cr",
    "mcap": "Micro Cap",
    "scripcode": 533543,
    "symbol": "BROOKS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE650L01011",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "68.08 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/brooks-lab-539063-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Brooks Lab. Sees Revision in Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/brooks-lab-downgraded-to-strong-sell-by-marketsmojo-amid-deteriorating-fundamentals-3741047",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BrooksLab_mojoScore_3741047.png",
        "date": "2025-12-02 10:09:46",
        "description": "Brooks Lab., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a complex interplay of financial and technical factors. The recent assessment highlights challenges in valuation and technical outlook, despite some positive financial trends, underscoring the nuanced position of the company within its sector."
      },
      {
        "title": "Why is Brooks Lab. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-brooks-lab-fallingrising-3732073",
        "imagepath": "",
        "date": "2025-11-27 00:29:40",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Movement and Market Outperformance</strong></p>\n<p>Brooks Laboratories’ recent price action stands out in the context of its sector and benchmark indices. Over the past week, the stock has gained 3.38%, significantly outperforming the Sensex’s modest 0.50% rise. Today’s 7.0% jump further extends this positive trend, marking the second consecutive day of gains that have cumulatively delivered an 11.23% return. The stock opened with an 8.65% gap up, signalling strong buying interest from the outset of trading.</p>\n<p>Intraday, the share price reached a high of ₹108.65, representing an 8.65% increase from the previous close. This intraday strength underscores robust demand, even as the weighted average price suggests that a larger volume of shares traded closer to the day’s low..."
      },
      {
        "title": "Brooks Laboratories Stock Falls to 52-Week Low of Rs.97.6",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/brooks-laboratories-stock-falls-to-52-week-low-of-rs976-3725551",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BrooksLaborator_priceRelatedfactors_3725551.png",
        "date": "2025-11-24 13:19:48",
        "description": "Brooks Laboratories has reached a new 52-week low of Rs.97.6, marking a significant decline in its stock price amid broader market gains. The pharmaceutical and biotechnology company’s shares have experienced a notable downturn over recent sessions, reflecting ongoing challenges in its financial performance and valuation metrics."
      },
      {
        "title": "Brooks Laboratories Q2 FY26: Sharp Profit Decline Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/result-analysis/brooks-laboratories-q2-fy26-sharp-profit-decline-amid-margin-pressures-3719317",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BrooksLaborator_quaterlyResult_3719317.png",
        "date": "2025-11-18 15:17:04",
        "description": "Brooks Laboratories Limited, a Baddi-based contract pharmaceutical manufacturer, reported a challenging second quarter for FY2026, with consolidated net profit plunging 16.70% quarter-on-quarter to ₹7.98 crores despite maintaining year-on-year growth momentum. The micro-cap pharmaceutical company, with a market capitalisation of ₹304.00 crores, saw its stock trading at ₹103.70 on November 18, down 48.87% from its 52-week high of ₹202.80, reflecting investor concerns over deteriorating operational metrics and sustained margin pressures."
      },
      {
        "title": "How has been the historical performance of Brooks Lab.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-brooks-lab-3702972",
        "imagepath": "",
        "date": "2025-11-14 23:40:30",
        "description": "Answer:\nThe historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years.\n\nBreakdown:\nBrooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar..."
      }
    ],
    "total": 242,
    "sid": "539063",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/brooks-laboratories-539063"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulation 2015- ITAT Orders.",
      "datetime": "30-Jan-2026",
      "details": "This is to inform you that the Company has received ITAT orders the details is provided in Annexure A.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015.",
      "datetime": "29-Jan-2026",
      "details": "Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 inter alia to consider and approve and take on record the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31 2025 along with Limited Review Report issued by the Statutory Auditors of the Company thereon.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "08-Jan-2026",
      "details": "Compliance Certificate under Regulation 74(5) of SEBI(Depositories and Participants) Regulations 2018 for the quarter ended 31st December 2025.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Brooks Laboratories Ltd has announced <strong>1:16</strong> rights issue, ex-date: 28 Jul 23",
          "dt": "2023-07-28",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Brooks Lab. Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-02 10:09:46

Brooks Lab., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a complex interplay of financial and technical factors. The recent assessment highlights challenges in valuation and technical outlook, despite some positive financial trends, underscoring the nuanced position of the company within its sector.

Why is Brooks Lab. falling/rising?

2025-11-27 00:29:40

Short-Term Price Movement and Market Outperformance Brooks Laboratories’ recent price action stands out in the context of its sector and benchmark indices. Over the past week, the stock has gained 3.38%, significantly outperforming the Sensex’s modest 0.50% rise. Today’s 7.0% jump further extends this positive trend, marking the second consecutive day of gains that have cumulatively delivered an 11.23% return. The stock opened with an 8.65% gap up, signalling strong buying interest from the outset of trading. Intraday, the share price reached a high of ₹108.65, representing an 8.65% increase from the previous close. This intraday strength underscores robust demand, even as the weighted average price suggests that a larger volume of shares traded closer to the day’s low...

Brooks Laboratories Stock Falls to 52-Week Low of Rs.97.6

2025-11-24 13:19:48

Brooks Laboratories has reached a new 52-week low of Rs.97.6, marking a significant decline in its stock price amid broader market gains. The pharmaceutical and biotechnology company’s shares have experienced a notable downturn over recent sessions, reflecting ongoing challenges in its financial performance and valuation metrics.

Brooks Laboratories Q2 FY26: Sharp Profit Decline Amid Margin Pressures

2025-11-18 15:17:04

Brooks Laboratories Limited, a Baddi-based contract pharmaceutical manufacturer, reported a challenging second quarter for FY2026, with consolidated net profit plunging 16.70% quarter-on-quarter to ₹7.98 crores despite maintaining year-on-year growth momentum. The micro-cap pharmaceutical company, with a market capitalisation of ₹304.00 crores, saw its stock trading at ₹103.70 on November 18, down 48.87% from its 52-week high of ₹202.80, reflecting investor concerns over deteriorating operational metrics and sustained margin pressures.

How has been the historical performance of Brooks Lab.?

2025-11-14 23:40:30

Answer: The historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years. Breakdown: Brooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar...

View All News